Blog | HemaCare

HemaCare PBMCs used for 3D Anti-Tumor Discovery Platform

Sep 28, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Cryopreservation, PBMCs, T Cells, Immunotherapy (Immunology)

0 Comments

An independent publication cites the use of HemaCare-sourced PBMC as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity. [1]

The paper, published in the renowned scientific journal Nature, reports the study results of a scientific team working at Novartis in San Diego. Their goal is to develop a discovery platform that more closely mimics the in-vivo tumor microenvironment.

Read More

Cancer CAR T Cell Therapy Adapted to Help Fight Threatening Fungal Infections

Sep 14, 2021 10:00:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, CAR-T, T Cells, Immunotherapy (Immunology)

0 Comments

Cryptococcus fungi infections can be fatal as the immune system struggles to fight off the invaders, but through immunotherapy called CAR T cell therapy, researchers are seeing positive results.

Cryptococcosis, a systemic fungal infection, is caused by the polysaccharide encapsulated yeasts Cryptococcus gatti and Cryptococcus neoformans. The disease can cause pneumonia and meningitis, as well as pathology in other tissues.

Read More

Higher Post-Immunotherapy Survival Rate in Cases of Recurrent Glioblastoma Linked to Low TMB

Jun 22, 2021 10:30:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy (Immunology)

0 Comments

A report out of Nature Communications suggests a correlation between the use of low TMB and an increased survival rate among glioblastoma patients may be due to changes in the immunological status of tumor post therapy.

Tumor mutation burden (TMB) is the frequency of certain protein (tumor antigen)-altering mutations within tumor genes. The production of more tumor antigens increases the chances that one or more of those can be recognized and reacted upon by the immune system. Highly mutated tumors produce many antigens that can stimulate T cells to respond to the antigens.

Read More

New Treatment Options May Lead to Dramatic Increase in Survival Rate for Patients Receiving Immunotherapy for NSCLC

Apr 20, 2021 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Immunotherapy (Immunology)

0 Comments

A study showed that patients who have received immunotherapy for non-small cell lung cancer can get more than one immune relative side effect.

The most common form of lung cancer is non-small cell lung cancer (NSCLC). It is divided into four stages, depending on the lung tumor’s size and location(s). Surgery and chemotherapy are common approaches to treatment, but newer approaches such as targeted therapy and immunotherapy provide promising survival benefits for patients with NSCLC.

Read More

HemaCare Publication Shines the Spotlight on Dedicated Donors

Apr 15, 2021 10:07:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing, Immunotherapy (Immunology)

0 Comments

HemaCare scientists have just published a white paper on a new raw material sourcing paradigm that they hope will transform the industry.

The publication centers on dedicated donors; recallable donors who are reserved to specific research programs. The basic premise is that clients will be able to reserve self-identified recallable donors who possess physiological or demographic traits deemed beneficial to a particular research program.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts